Summary
- Smith & Nephew recently agreed to acquire all outstanding shares of Osiris Therapeutics for $660 million.
- The deal fits within my 5-criteria framework for forecasting mergers & acquisitions.
- I also share my insight on the potential buyout of Vericel and BioLife Solutions, as well as other candidates for 2019.
- Looking for more? I update all of my investing ideas and strategies to members of Integrated BioSci Investing. Start your free trial today »
In the long run, it's not just how much money you make that will determine your future prosperity. It's how much of that money you put to work by saving it and investing it.
- Peter Lynch (stellar value and growth investor)
On March 12, 2019, Osiris Therapeutics (OSIR) disclosed that Smith & Nephew (SNN) agreed to acquire the company for $660 million. At this price, the buyout equates to $19.0 per common share. Prior to this news, I recommended Osiris to Integrated BioSci Investing members. My strong optimism on Osiris is due to the unprecedented efficacy of its regenerative medicine for diabetic wound management. Subsequent to this catalyst, a notable IBI community leader raised the acquisition possibility of two similar bioscience stocks: BioLife Solutions (BLFS) and Vericel Corp. (VCEL). In my opinion, these firms have highly interesting prospects. Hence, I'll present an M&A analysis of Osiris through the 5-criteria framework. And I'll touch upon the M&A prospects of Vericel.
